When is targeted therapy recommended for multiple myeloma?

Multiple myeloma is a blood cancer involving plasma cells in the bone marrow. Treatment decisions reflect symptoms, blood and urine findings, kidney function, bone health, previous treatment, and whether the disease is newly active or has returned. Targeted medicines act on features that help myeloma cells survive or on the surrounding marrow environment. They are often part of a combination plan, and the choice may change if the disease stops responding or side effects become difficult. Support for bones, infections, pain, and anaemia may be needed alongside cancer treatment.

Ask what the treatment is intended to achieve and which medicines will be combined with it. Discuss kidney monitoring, clot prevention when relevant, infection precautions, and how to recognise nerve symptoms or allergic reactions. Bring a full medicine and supplement list to every review. Ask how blood tests, urine tests, and symptoms will show whether the plan is helping. Explore [Multiple Myeloma](/conditions/multiple-myeloma/) and [Targeted Therapy](/treatments/systemic-therapy/targeted-therapy/).

Call the treatment team promptly for fever, new infection symptoms, unusual bruising, worsening weakness, reduced urine, severe constipation, or new numbness or weakness. Seek urgent help for sudden chest pain, severe breathlessness, confusion, a new inability to walk, or a possible spinal cord problem. Never change a treatment schedule without the haematology team.

What is the current treatment goal? Why is this targeted medicine suitable now? How will kidney function and blood counts be followed? Which symptoms need urgent assessment?